Orphinic selects promising projects in therapeutics, MedTech, and e-Health, verifies research hypotheses through clinical trials, and partners with large pharmaceutical companies.

Orphinic

Orphinic Scientific S.A. was funded in 2019 as the first Polish biotech portfolio platform creating innovative solutions for orphan diseases and other indications with significant unmet medical needs in the clinical trial phase. 
Orphinic core scientific team consist of experts with over 20 years experience in clinical development processes and their commercialization. The company’s competencies in clinical stage development are further enforced through a collaboration with a large clinical CRO operating in the CEE region. This facilitates access to diverse patient populations and rapid enrollment to clinical trials supporting our projects and significantly shortens the duration of individual phases.
Orphinic currently has 8 projects in the pipeline that range from a preclinical phase to market approval stages in three healthcare segments: therapeutics, medtech and e-health.

⏱ We shorten time to the market due to specialized healthcare centers in CEE and an affiliated CRO. 
🩺 Our team has an exceptional track record in sourcing and exiting high-quality projects. 
🧬 Our portfolio represents clinic-ready assets, with first projects ready to exit in 2023, and a preclinical pipeline for long-term value creation.
💊 We invest in projects with low correlation. Average project risk of c.50% with average returns of c.10x our investment.
📈 Our plan is to IPO at Warsaw Stock Exchange by the end of 2022.
 

Orphinic Scientific

👉 "We will eventually cope with cancer 🦀, the challenge is to maintain cognitive functions 🙇. In an ideal world, medical students 👩‍⚕️ will learn primarily how to communicate with patients🤳 , leaving the diagnosis to the power of artificial intelligence that analyzes medical data in a second 🤖,"  believes Adam Kruszewski, MD,  CEO and co-founder of the biotechnology holding Orphinic Scientific. His essay on medicine of the future was published by the mZdrowie.pl.
📕 https://lnkd.in/d95STW34

The BIO International Convention is the largest and most comprehensive event for biotechnology. Let's meet 🤝

#BIO2024 #BioTech #OneonOne #Partnering

📣 As you already know💡, Orphinic Scientific became a finalist of the "Entrepreneur of the Year of the University of Warsaw" competition in the start-up category three weeks ago 🏆.

👉 "We are a company that helps inventors fulfill their dreams and commercialize new drug therapies. In addition, as a firm from Poland, we entered the world's first league," says Adam Kruszewski, CEO of Orphinic.

🎥 Watch our short video: https://lnkd.in/deeyY3T4.

Orphinic Scientific portfolio company DEBN Sp. z o.o. has announced the start of clinical trials of DEBN, the first medical device that enables simultaneous organ-targeted delivery of antibiotics during prostate biopsy procedures.
This innovation comes at a critical time as new research forecasts that global deaths from prostate cancer will almost double in the next 20 years. 

Read more about it here: https://lnkd.in/gdh_H9WA
#ProstateCancer #MedicalDevice #ClinicalTrials #Innovation

ORPH

COM:ORPHINIC

Orphinic